References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

10.3322/caac.21834 · 2024 · External reference

BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients

10.1016/j.cca.2020.11.023 · 2021 · External reference

Beyond genetics: exploring the role of epigenetic alterations in breast cancer

10.1016/j.prp.2024.155174 · 2024 · External reference

Liquid biopsy and minimal residual disease—latest advances and implications for cure

10.1038/s41571-019-0187-3 · 2019 · External reference

Liquid biopsy in cancer management: Integrating diagnostics and clinical applications

10.1016/j.plabm.2024.e00446 · 2025 · External reference

Immuno-oncology biomarkers for personalized immunotherapy in breast cancer

10.3389/fcell.2020.00162 · 2020 · External reference

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands

10.1177/25151355231192043 · 2023 · External reference

Immune checkpoint inhibitors: key trials and an emerging role in breast cancer

10.1016/j.semcancer.2020.06.016 · 2020 · External reference

The expression pattern and clinical significance of the immune checkpoint regulator VISTA in human breast cancer

10.3389/fimmu.2020.563044 · 2020 · External reference

Programmed cell death-1 and its ligands: current knowledge and possibilities in immunotherapy

10.1016/j.clinsp.2023.100177 · 2023 · External reference

Exploring immune checkpoint inhibitors: focus on PD-1/PD-L1 axis and beyond

10.1016/j.prp.2025.155864 · 2025 · External reference

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

10.1186/s40164-025-00627-6 · 2025 · External reference

The role of PD-1 signaling in health and immune-related diseases

10.3389/fimmu.2023.1163633 · 2023 · External reference

Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy

10.3389/fimmu.2020.587460 · 2020 · External reference

Immunotropic therapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in the treatment of cancers. Part 1: immunologic aspects

10.17816/maj641689 · 2025 · External reference

PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL

10.1038/s41375-024-02271-1 · 2024 · External reference

PD-1 negatively tunes macrophage immune activation by turning off JNK and STAT1 signaling: exploited by Leishmania for its intra-macrophage survival

10.1016/j.cellimm.2023.104758 · 2023 · External reference

The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: based on the innate and adaptive immune components

10.1016/j.biopha.2023.115569 · 2023 · External reference

Immunotherapy in breast cancer

10.4103/jcar.jcar_2_19 · 2019 · External reference

Clinical data on immunotherapy in breast cancer

10.1159/000511788 · 2020 · External reference

The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment

10.3389/fimmu.2020.568931 · 2020 · External reference

Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma

10.1016/j.oor.2024.100650 · 2024 · External reference

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma

10.1016/j.annonc.2019.09.005 · 2020 · External reference

An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3

10.1016/j.intimp.2023.111280 · 2024 · External reference

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

10.1186/s13046-024-03074-z · 2024 · External reference

Spatial and temporal changes in PD-L1 expression in cancer: the role of genetic drivers, tumor microenvironment and resistance to therapy

10.3390/ijms21197139 · 2020 · External reference

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients

10.1080/20013078.2019.1710899 · 2020 · External reference

Soluble PD-L1: from immune evasion to cancer therapy

10.3390/life15040626 · 2025 · External reference

Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma

10.1007/s10517-019-04349-8 · 2019 · External reference

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

10.1016/j.critrevonc.2019.08.009 · 2019 · External reference

High serum levels of soluble PD-1 and PD-L1 are associated with advanced clinical stages in patients with cervical cancer

10.3892/br.2025.1948 · 2025 · External reference

Regulation of PD-1 in T cells for cancer immunotherapy

10.1016/j.ejphar.2020.173240 · 2020 · External reference

Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy

2020 · External reference

Molecular and cellular functions of long non-coding RNAs in prostate and breast cancer

2022 · External reference

Decoding lncRNA-mediated epigenetic rewiring of protein lysine methyltransferases in cancer: a comprehensive review of mechanisms and therapeutic implications

10.1016/j.ijbiomac.2026.152625 · 2026 · External reference

Interactome battling of lncRNA CCDC144NL-AS1: its role in the emergence and ferocity of cancer and beyond

10.1016/j.ijbiomac.2022.09.209 · 2022 · External reference

CCDC144NL-AS1/hsa-miR-143-3p/HMGA2 interaction: in-silico and clinically implicated in CRC progression, correlated to tumor stage and size in case-controlled study; step toward ncRNA precision

10.1016/j.ijbiomac.2023.126739 · 2023 · External reference

lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression

10.1038/s41598-020-64713-x · 2020 · External reference

LncRNA AFAP1-AS1 promotes the progression of colorectal cancer through miR-195-5p and WISP1

10.1155/2021/6242798 · 2021 · External reference

The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway

10.32604/or.2023.028256 · 2023 · External reference

Two antisense RNAs—AFAP1-AS1 and MLK7-AS1—promote colorectal cancer progression by sponging miR-149-5p and miR-485-5p

10.1016/j.omtn.2023.07.004 · 2023 · External reference

American Joint Committee on Cancer’s staging system for breast cancer, eighth edition: summary for clinicians

10.4274/ejbh.galenos.2021.2021-4-3 · 2021 · External reference

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update

10.1200/jco.19.02309 · 2020 · External reference

Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update

10.1200/jco.22.02864 · 2023 · External reference

Pharmacological treatment of early-stage breast cancer: key discussions at the 19th International St. Gallen Consensus Conference

10.1007/s00761-025-01879-x · 2026 · External reference

Liquid biopsy for cancer immunotherapy: biomarkers to predict and monitor response upon immune checkpoint blockade

10.1016/j.ccr.2025.216767 · 2025 · External reference

The role of LncRNAs in tumor immunotherapy

10.1186/s12935-023-02872-3 · 2023 · External reference

The expression and function of long noncoding RNAs in hepatocellular carcinoma

10.1002/cai2.90 · 2023 · External reference

LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P

10.1038/s41388-019-0812-8 · 2019 · External reference

Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells

10.1038/s41556-019-0299-0 · 2019 · External reference

The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation

10.1126/sciadv.aat9820 · 2019 · External reference

The role of long non-coding RNA H19 in breast cancer

10.3892/ol.2019.11093 · 2020 · External reference

Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis

10.1038/s41598-024-52953-0 · 2024 · External reference

LncRNA DDX11-AS1 promotes breast cancer progression by targeting the miR-30c-5p/MTDH axis

10.1038/s41598-024-78413-3 · 2024 · External reference

Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?

10.1016/bs.pmbts.2024.02.003 · 2024 · External reference

Non-coding RNAs as potential therapeutic targets in breast cancer

10.1016/j.bbagrm.2019.04.005 · 2020 · External reference

The current advances of lncRNAs in breast cancer immunobiology research

10.3389/fimmu.2023.1194300 · 2023 · External reference

The lncRNA AFAP1-AS1 is upregulated in metastatic triple-negative breast tumors and controls hypoxia-activated vasculogenic mimicry and angiogenesis

10.1186/s12885-024-13019-6 · 2024 · External reference

Expression analysis of AFAP1-AS1 and AFAP1 in breast cancer

10.3233/cbm-170831 · 2018 · External reference

Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer

10.1007/s12282-018-0891-3 · 2019 · External reference

Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer

10.1038/s41419-021-03917-z · 2021 · External reference

LncRNA AFAP1-AS1 knockdown represses cell proliferation, migration, and induced apoptosis in breast cancer by downregulating SEPT2 via sponging miR-497-5p

10.1089/cbr.2020.3688 · 2022 · External reference

SP1-induced upregulation of LncRNA AFAP1-AS1 promotes tumor progression in triple-negative breast cancer by regulating mTOR pathway

10.3390/ijms241713401 · 2023 · External reference

FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring exosomal lncRNA AFAP1-AS1

10.1002/mc.23782 · 2024 · External reference

Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc

10.1038/s41392-021-00562-y · 2021 · External reference

Non-coding RNA and immune-checkpoint inhibitors: friends or foes?

10.2217/imt-2019-0204 · 2020 · External reference

Prognostic value and immunological role of PD-L1 gene in pan-cancer

10.1186/s12885-023-11267-6 · 2024 · External reference

Programmed death-ligand 1 mediates triple-negative breast cancer metastasis and stemness through ten-eleven translocation 3

10.1016/j.ijbiomac.2025.148791 · 2025 · External reference

MicroRNA-561-3p indirectly regulates the PD-L1 expression by targeting ZEB1, HIF1A, and MYC genes in breast cancer

10.1038/s41598-024-56511-6 · 2024 · External reference

The prevalence of PD-L1 expression in triple-negative breast cancer patients and its correlation with survival rates and other prognostic factors: a survival analysis

10.4103/abr.abr_2_24 · 2024 · External reference

Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis

10.1007/s10549-019-05371-0 · 2019 · External reference

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

10.1007/s00262-021-02898-4 · 2021 · External reference

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

10.1007/s00262-018-2271-4 · 2019 · External reference

Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression

10.1245/s10434-018-07112-x · 2019 · External reference

High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer

10.1002/cam4.2789 · 2020 · External reference

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer

10.1038/s41598-019-47330-1 · 2019 · External reference

PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs

10.1016/j.lfs.2020.117899 · 2020 · External reference

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas

10.1038/s41598-020-65895-0 · 2020 · External reference

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

10.1038/s41598-021-99311-y · 2021 · External reference

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

10.1007/s00262-021-02898-4 · 2021 · External reference

Thymoquinone, a novel multi-strike inhibitor of pro-tumorigenic breast cancer (BC) markers: CALR, NLRP3 pathway and sPD-L1 in PBMCs of HR+ and TNBC patients

10.3390/ijms241814254 · 2023 · External reference

Serum sPD-1 and sPD-L1 as biomarkers for evaluating the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients

10.1016/j.clbc.2019.03.008 · 2019 · External reference

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer

10.1186/s12967-023-03879-0 · 2023 · External reference

Improved method for prioritization of disease associated lncRNAs based on ceRNA theory and functional genomics data

10.18632/oncotarget.13964 · 2017 · External reference

Predicting lymph node metastasis and prognosis of individual cancer patients based on miRNA-mediated RNA interactions

10.1186/s12920-022-01231-x · 2022 · External reference

Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma

10.18632/oncotarget.16545 · 2017 · External reference

A review on the role of AFAP1-AS1 in the pathoetiology of cancer

10.3389/fonc.2021.777849 · 2021 · External reference

Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity

10.3390/cancers15010184 · 2023 · External reference

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy

10.1186/s12943-021-01406-7 · 2021 · External reference

Molecular subtypes of breast cancer: a review for breast radiologists

10.1093/jbi/wbaa110 · 2020 · External reference

Advancements in human breast cancer targeted therapy and immunotherapy

10.7150/jca.64205 · 2021 · External reference